Neovacs

Report Publication Announcement • Jan 26, 2015

PRESS RELEASE PRESS RELEASE PRESS RELEASE

2015 Financial Calendar

Paris, January 26, 2015 – NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2015.

Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.

• 2014 Full-Year Results February 27, 2015 Shareholders' AGM April 8, 2015
• 2015 Half-Year results September 4, 2015

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

Neovacs Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com

Investor Relations – Financial Communications Germany – MC Services Raimund Gabriel +49-89-210228-30 raimund.gabriel@mc-services.eu

Press – U.S. Inquiries – The Ruth Group Melanie Sollid-Penton 1.646.536.7023 msollid@theruthgroup.com